Aditoprime (Aditoprim) is a selective inhibitor of bacterial dihydrofolate reductase (DHFR) that inhibits the transformation of dihydrofolic acid to tetrahydrofolic acid. Aditoprime shows good antibacterial activity and broad antimicrobial spectrum, and moreover, excellent pharmacokinetics. Aditoprime inhibits L.casei and E.coli DHFR with IC 50 of 520 and 47 nM, respectively [1] [2] [3].

Aditoprime has the same antibacterial spectrum as TMP. Salmonellaand Streptococcus from swine, E. coli and Salmonella from chickens, E. coli, Streptococcus, Mannheimia, and Pasteurella from calves, Streptococcus and Mannheimia from sheep, and E. coli, Flavobacterium columnare, A. baumannii and Y. ruckeri from fishes are highly susceptible to Aditoprime (MIC or MIC 50 ≤ 4 μg/mL) [1].

Aditoprime (Aditoprim) has longer elimination half-lives (3.3~14.8 h) and higher distribution volumes (4.6~10.4 L/kg) than those of Trimethoprim (TMP) in pig, calf, monkey, sheep and some other animal species, and a similar pattern is observed for Aditoprime where the distribution volume is about four times higher than that of TMP [1]. Aditoprime (10 -40 mg/kg; b.w.; intramuscularly) shows efficacy in infected swine (swine streptococcosis) [1].